CLS Therapeutics is a biopharmaceutical company focused to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.

The company’s first-in-class lead candidate CLS-014  is a novel adeno-associated vector  encoding biologically enhanced DNase I enzyme designed  to clean deadly circulating extracellular DNA from patient blood.

We are translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers with unmet medical needs, beginning with our first program for pancreatic cancer.

CLS Therapeutics, founded by a team of scientists and biotech entrepreneurs and guided by the team comprised of the brightest minds in the field of oncology and gene therapy, is committed to advancing cutting-edge research  to help cancer patients.